Premium
CLINICAL TRIAL OF A BETA‐RECEPTOR BLOCKING AGENT (LB 46) IN MIGRAINE PROPHYLAXIS
Author(s) -
Sjaastad Ottar,
Stensrud Per
Publication year - 1972
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1972.tb07532.x
Subject(s) - migraine , placebo , medicine , blocking (statistics) , clinical trial , anesthesia , beta (programming language) , double blind , pathology , alternative medicine , statistics , mathematics , computer science , programming language
Twenty‐four patients were treated with a beta‐blocking agent (Viskén, LB 46 Sandoz) and placebo in double‐blind study. The dosage of Viskén was 15 mg in 11 patients and 7.5 mg in 13 patients, and each remedy was taken for 4 weeks with an interposed 3‐week “wash‐out” period. There was generally no definite change in migraine attack‐frequency or pattern during Viskén medication. Three patients, however, had a remarkably reduced number of attacks on Viskén. This reduction may or may not have been due to Viskén.